ERBB2 and breast cancer: Similarly, in the phase II NeoATP trial, 53 patients with HER2+ local advanced BC (stage IIA–IIIC) achieved a pCR rate of 69.81% after undergoing NAT with pyrotinib plus trastuzumab and paclitaxel-cisplatin (Yin et al., 2022).